• Something wrong with this record ?

The effect of gabapentin and pregabalin on bone turnover and bone strength: A prospective study in Wistar rats

J. Simko, I. Karesova, J. Kremlacek, Z. Eva, J. Horacek, S. Fekete, J. Malakova, H. Zivna, V. Palicka,

. 2019 ; 71 (6) : 1213-1218. [pub] 20190815

Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc20023441

BACKGROUND: There are limited data on the effects of GBP on bone and no data for PGB. Some data suggest that there is a significant influence of sex hormone balance on the susceptibility of bone to antiepileptic drug-induced bone loss. METHODS: Forty-eight male Wistar rats were divided into six groups that were subjected to two surgeries, sham (noORX) or real orchidectomy (ORX), and were fed three diets, a SLD, a SLD enriched with GBP or a SLD enriched with PGB. Dual energy X-ray absorptiometry was used to measure the bone mineral density. The concentrations of bone turnover markers were assayed. The femurs were biomechanically tested. RESULTS: Significant reductions in bone mineral density, weight and biomechanical strength were observed in ORX animals. GBP or PGB exposure did not cause significant alterations in bone mineral density or biomechanical strength. No changes in bone turnover markers were observed, except for RANKL. A significant increase was found in the ORX GBP and ORX PGB groups. Within the orchidectomized animal group, RANKL levels were significantly higher in the ORX PGB group than in the ORX GBP group. CONCLUSIONS: Because neither GBP nor PGB affected bone mineral density or mechanical bone strength, both of these antiepileptic drugs could be considered drugs with lower risks to bone health. A shift in RANKL levels indicates that the effects of GBP and PGB on osteoclast activity may be dependent on the hormonal status of animals.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20023441
003      
CZ-PrNML
005      
20201214130042.0
007      
ta
008      
201125s2019 sz f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.pharep.2019.08.004 $2 doi
035    __
$a (PubMed)31669885
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Simko, Julius $u Department of Neurology, Charles University, Faculty of Medicine and University Hospital, Hradec Kralove, Czech Republic. Electronic address: simko.julius@gmail.com.
245    14
$a The effect of gabapentin and pregabalin on bone turnover and bone strength: A prospective study in Wistar rats / $c J. Simko, I. Karesova, J. Kremlacek, Z. Eva, J. Horacek, S. Fekete, J. Malakova, H. Zivna, V. Palicka,
520    9_
$a BACKGROUND: There are limited data on the effects of GBP on bone and no data for PGB. Some data suggest that there is a significant influence of sex hormone balance on the susceptibility of bone to antiepileptic drug-induced bone loss. METHODS: Forty-eight male Wistar rats were divided into six groups that were subjected to two surgeries, sham (noORX) or real orchidectomy (ORX), and were fed three diets, a SLD, a SLD enriched with GBP or a SLD enriched with PGB. Dual energy X-ray absorptiometry was used to measure the bone mineral density. The concentrations of bone turnover markers were assayed. The femurs were biomechanically tested. RESULTS: Significant reductions in bone mineral density, weight and biomechanical strength were observed in ORX animals. GBP or PGB exposure did not cause significant alterations in bone mineral density or biomechanical strength. No changes in bone turnover markers were observed, except for RANKL. A significant increase was found in the ORX GBP and ORX PGB groups. Within the orchidectomized animal group, RANKL levels were significantly higher in the ORX PGB group than in the ORX GBP group. CONCLUSIONS: Because neither GBP nor PGB affected bone mineral density or mechanical bone strength, both of these antiepileptic drugs could be considered drugs with lower risks to bone health. A shift in RANKL levels indicates that the effects of GBP and PGB on osteoclast activity may be dependent on the hormonal status of animals.
650    _2
$a absorpční fotometrie $x metody $7 D015502
650    _2
$a alkalická fosfatasa $x metabolismus $7 D000469
650    _2
$a zvířata $7 D000818
650    _2
$a antikonvulziva $x farmakologie $7 D000927
650    _2
$a biomechanika $x účinky léků $7 D001696
650    _2
$a kostní denzita $x účinky léků $7 D015519
650    _2
$a remodelace kosti $x účinky léků $7 D016723
650    _2
$a femur $x účinky léků $x metabolismus $7 D005269
650    _2
$a gabapentin $x farmakologie $7 D000077206
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a orchiektomie $x metody $7 D009919
650    _2
$a osteoprotegerin $x metabolismus $7 D053244
650    _2
$a pregabalin $x farmakologie $7 D000069583
650    _2
$a prospektivní studie $7 D011446
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Wistar $7 D017208
655    _2
$a časopisecké články $7 D016428
700    1_
$a Karesova, Iva $u Institute of Clinical Biochemistry and Diagnostics, Charles University, Faculty of Medicine and University Hospital, Hradec Kralove, Czech Republic.
700    1_
$a Kremlacek, Jan $u Department of Pathophysiology, Charles University, Faculty of Medicine, Hradec Kralove, Czech Republic.
700    1_
$a Eva, Zimcikova $u Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Kralove, Charles University, Prague, Czech Republic.
700    1_
$a Horacek, Jiri $u Department of Internal Medicine - Hematology, Charles University, Faculty of Medicine and University Hospital, Hradec Kralove, Czech Republic.
700    1_
$a Fekete, Sona $u Institute of Clinical Biochemistry and Diagnostics, Charles University, Faculty of Medicine and University Hospital, Hradec Kralove, Czech Republic.
700    1_
$a Malakova, Jana $u Institute of Clinical Biochemistry and Diagnostics, Charles University, Faculty of Medicine and University Hospital, Hradec Kralove, Czech Republic.
700    1_
$a Zivna, Helena $u Radioisotope Laboratories and Vivarium, Charles University, Faculty of Medicine and University Hospital, Hradec Kralove, Czech Republic.
700    1_
$a Palicka, Vladimir $u Institute of Clinical Biochemistry and Diagnostics, Charles University, Faculty of Medicine and University Hospital, Hradec Kralove, Czech Republic.
773    0_
$w MED00165879 $t Pharmacological reports : PR $x 1734-1140 $g Roč. 71, č. 6 (2019), s. 1213-1218
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31669885 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201214130041 $b ABA008
999    __
$a ok $b bmc $g 1595760 $s 1114117
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 71 $c 6 $d 1213-1218 $e 20190815 $i 1734-1140 $m Pharmacol. Reports $n Pharmacol. Rep. $x MED00165879
LZP    __
$a Pubmed-20201125

Find record

Citation metrics

Archiving options